New World cutaneous leishmaniasis: Updated review of current and future diagnosis and treatment

Journal of the American Academy of Dermatology

Volumn 63, Issue 2, 2010, Pages 309-322

  Mitropoulos, Panagiotis ^a   Konidas, Pete ^a   Durkin Konidas, Mindy ^a  

^a Camp Long Troop Medical Clinic   (South Korea)

Author keywords

cutaneous; diagnosis; leishmaniasis; New World; treatment

Indexed keywords

ALKALOID; ALLOPURINOL; ALLOPURINOL RIBOSIDE; AMPHOTERICIN B LIPID COMPLEX; ANTIMONY; CHALCONE; CYCLOSPORIN; DAPSONE; FLUCONAZOLE; GENTAMICIN; IMIQUIMOD; ITRACONAZOLE; KETOCONAZOLE; MEGLUMINE; MEGLUMINE ANTIMONATE; METHYLBENZETHONIUM CHLORIDE; MILTEFOSINE; MONOCLONAL ANTIBODY; NIFURTIMOX; PAROMOMYCIN; PENTAMIDINE; PENTAMIDINE ISETHIONATE; PENTOSAM; PROBENECID; RECOMBINANT INTERFERON; RESIQUIMOD; RIFAMPICIN; STIBOGLUCONATE SODIUM; TERPENE; UNCLASSIFIED DRUG; UNINDEXED DRUG; UREA; ANTIAMEBIC AGENT; ANTIFUNGAL AGENT; ANTIPROTOZOAL AGENT; LEISHMANIA VACCINE;

ACTINIC KERATOSIS; ADJUVANT THERAPY; AMASTIGOTE; AMEBIASIS; ANTHRAX; ATYPICAL MYCOBACTERIOSIS; BASAL CELL CARCINOMA; BLASTOMYCOSIS; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; COMBINATION CHEMOTHERAPY; CONDYLOMA ACUMINATUM; CRYOTHERAPY; CRYPTOSPORIDIOSIS; CURETTAGE; DESICCATION; DIFFERENTIAL DIAGNOSIS; DRUG COST; DRUG EFFICACY; ECTHYMA; FOLLOW UP; FRENCH GUIANA; GIARDIASIS; GOUT; HEATING; HUMAN; INSECT BITE; LEISHMANIA; LEISHMANIA BRAZILIENSIS; LEISHMANIA CHAGASI; LEISHMANIA DONOVANI; LEISHMANIA INFANTUM; LEISHMANIA MAJOR; LEISHMANIA MEXICANA; LEISHMANIA PANAMENSIS; LEISHMANIA TROPICA; LOW DRUG DOSE; LUPUS VULGARIS; MONOTHERAPY; MYIASIS; NEPHROTOXICITY; NONHUMAN; PHOTODYNAMIC THERAPY; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PROMASTIGOTE; REVIEW; SARCOIDOSIS; SKIN CANCER; SKIN LEISHMANIASIS; SKIN TUBERCULOSIS; SPOROTRICHOSIS; SYPHILIS; SYSTEMATIC REVIEW; TULAREMIA; VISCERAL LEISHMANIASIS; YAWS;

AMEBICIDES; ANTIFUNGAL AGENTS; ANTIPROTOZOAL AGENTS; HUMANS; LEISHMANIASIS VACCINES; LEISHMANIASIS, CUTANEOUS;

EID: 77955289005     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2009.06.088     Document Type: Review

References (106)

1. P. Desjeux The increase in risk factors for leishmaniasis worldwide Trans R Soc Trop Med Hyg 95 2001 239 243 (Pubitemid 33713068)
2. C.M. Choi, and E.A. Lerner Leishmaniasis as an emerging infection J Investig Dermatol Symp Proc 6 2001 175 182
3. Hsia R. Leishmaniasis. Available from: URL: http://www.emedicine.com/ emerg/topic296.htm. Accessed on March 23, 2009.
4. Centers for Disease Control and Prevention (CDC). The yellow book, health information for travelers, CDC 2010. Available at http://wwwnc.cdc.gov/travel/ yellowbook/2010/chapter-5/cutaneous-leishmaniasis.aspx. Accessed February 8, 2010.
5. C. David, L. Dimier-David, F. Vargas, M. Torrez, and J.P. Dedet Fifteen years of cutaneous mucocutaneous leishmaniasis in Bolivia: a retrospective study Trans R Soc Trop Med Hyg 87 1993 7 9 (Pubitemid 23093046)
6. M.M. Lessa, H.A. Lessa, T.W. Castro, A. Oliveira, A. Scherifer, and P. Machado et al. Mucosal leishmaniasis: epidemiological and clinical aspects Braz J Otorhinolaryngol 73 2007 843 847
7. C.R. Davies, R. Reithinger, D. Campbell-Lendrum, D. Feliciangeli, R. Borges, and N. Rodriguez The epidemiology and control of leishmaniasis in Andean countries Cad Saude Publica 16 2000 925 950
8. A. Jorquera, E. Ledezma, L. De Sousa, A. Garcia, J. Sanchez, and J. Zerpa Epidemiologic characterization of American cutaneous leishmaniasis in an endemic region of eastern Venezuela Am J Trop Med Hyg 58 1998 589 593 (Pubitemid 28237256)
9. C.P. McHugh Leishmaniasis in Washington County Texas. J Am Acad Dermatol 47 2002 614 616
10. N.A. Wright, L.E. Davis, K.S. Aftergut, C.A. Parrish, and C.J. Cockerell Cutaneous leishmaniasis in Texas: a northern spread of endemic areas J Am Acad Dermatol 58 2008 650 652
11. S.H. Ghosn, and A.K. Kurban K. Wolff, L.A. Goldsmith, S.I. Katz, B.A. Gilchrest, A.S. Paller, D.J. Leffell, editors. Fitzpatrick's dermatology in general medicine 7th ed Leishmaniasis and other protozoan infections Vol 11 2008 McGraw Hill Inc New York, NY 2001 2009
12. K.R. Beenal, V. Ramesh, and A. Mukherjee Identification of parasite antigen, correlation of parasite density and inflammation in skin lesions of post kala-azar dermal leishmaniasis J Cutan Pathol 30 2003 616 620 (Pubitemid 37372349)
13. N. Courret, T. Lang, G. Milon, and J.C. Antoine Intradermal inoculations of low doses of Leishmania major and Leishmania amazonensis metacyclic promastigotes induce different processes and status protection in BALB/c mice Int J Parasitol 33 2003 1373 1383 (Pubitemid 37176982)
14. E. Schwartz, H. Cristoph, and J. Blum New World cutaneous leishmaniasis in travelers Lancet Infect Dis 6 2006 342 349
15. S.D. Lawn, J. Whetham, P.L. Chiodini, J. Kanagalingam, J. Watson, and R.H. Behrens et al. New World mucosal and cutaneous leishmaniasis: an emerging health problem among British travelers QJM 97 2004 781 788
16. B.L. Herwaldt Leishmaniasis. Lancet 354 1999 1191 1199
17. N.C. Hepburn Cutaneous leishmaniasis: an overview J Postgrad Med 49 2003 50 54
18. S.L. Croft, S. Sundar, and A.H. Fairlamb Drug resistance in leishmaniasis Clin Microbiol Rev 19 2006 111 126 (Pubitemid 43157649)
19. A. Llanos-Cuentas, G. Tulliano, R. Araujo-Castillo, C. Miranda-Verastegui, G. Santamaria-Castrellon, and L. Ramirez et al. Clinical and parasite species risk factors for pentavalent antimonial treatment failure in cutaneous leishmaniasis in Peru Clin Infect Dis 46 2008 223 231
20. R. Rojas, L. Valderrama, M. Valderrama, M.X. Varona, M. Ouellette, and N.G. Saravia Resistance to antimony and treatment failure in human Leishmania (viannia) infection J Infect Dis 193 2006 1375 1383 (Pubitemid 43673385)
21. A. Alkhwajah Recent trends in the treatment of cutaneous leishmaniasis Ann Saudi Med 18 1998 412 416 (Pubitemid 29043859)
22. D.K. Kochar, G. Saini, S.K. Kochar, P. Sirohi, R.A. Bumb, and R.D. Mehta et al. A double blind, randomized placebo controlled trial of rifampicin with omeprazole in the treatment of human cutaneous leishmaniasis J Vector Borne Dis 43 2006 161 167
23. D.K. Kochar, S. Aseri, B.V. Sharma, R.A. Bumb, R.D. Mehta, and S.K. Purohit The role of rifampicin in the management of cutaneous leishmaniasis QJM 93 2000 733 737
24. L.E. Osorio, R. Palacios, M.E. Chica, and M.T. Ochoa Treatment of cutaneous leishmaniasis in Colombia with dapsone Lancet 351 1998 498 499
25. M.F.V. Guena, P.D. Marsden, C.C. Cuba, and A.C. Barreto Further trials of nifurtimox in mucocutaneous leishmaniasis Trans R Soc Trop Med Hyg 75 1981 335 337
26. R.E. Vasquez, and L. Soong CXCL10/gamma interferon-inducible protein 10-mediated protection against Leishmania amazonensis infection in mice Infect Immun 74 2006 6769 6777 (Pubitemid 44913151)
27. C. Anjili, B. Langat, P. Ngumbi, P.A. Mbati, J. Githure, and W.K. Tonui Effects of anti- Leishmania monoclonal antibodies on the development of Leishmania major in Phlebotomus duboscqi (Diptera: Psychodidae) East Afr Med J 83 2006 72 78 (Pubitemid 43700902)
28. L. Zhai, M. Chen, J. Blom, T.G. Theander, S.B. Christensen, and A. Kharazmi The antileishmanial activity of novel oxygenated chalcones and their mechanism of action J Antimicrob Chemother 43 1999 793 803
29. O.E. Akilov, S. Kosaka, K. O'Riordan, and T. Hasan Photodynamic therapy for cutaneous leishmaniasis: the effectiveness of topical phenothiaziniums in parasite eradication and Th1 immune response stimulation Photochem Photobiol Sci 6 2007 1067 1075
30. D.E. Claes, F. Clemens, J. Flory, N. Abedelmajeed, I. Arieh, and J.L. Charles et al. Treatment of cutaneous leishmaniasis with photodynamic therapy Arch Dermatol 139 2003 432 434
31. The Sanger Centre. Sequencing projects. Available from: URL: http://www.sanger.ac.uk/Projects/. Accessed March 25, 2009.
32. P.J. Myler, and N. Fasel Leishmania: after the genome 1st ed. 2008 Caister Academic Press Norfolk, UK
33. D.J. Wyler, and P.D. Marsden Leishmaniasis K.S. Warren, A.A.F. Mahmoud, editors. Tropical and geographical medicine 1984 McGraw-Hill Book Co New York 270 280
34. B.L. Herwaldt, and J.D. Berman Recommendations for treating leishmaniasis with sodium stibogluconate (Pentostam) and review of pertinent clinical studies Am J Trop Med Hyg 46 1992 296 306
35. J.D. Berman Treatment of New World cutaneous and mucosal leishmaniasis Clin Dermatol 14 1996 519 522
36. T.R. Navin, B.A. Arana, F.E. Arana, J.D. Berman, and J.F. Chajón Placebo-controlled clinical trial of sodium stibogluconate (Pentostam) versus ketoconazole for treating cutaneous leishmaniasis in Guatemala J Infect Dis 165 1992 528 534
37. E.M. Andersen, M. Cruz-Saldarriaga, A. Llanos-Cuentas, M. Luz-Cjuno, J. Echevarria, and C. Miranda-Verastegui et al. Comparison of meglumine antimoniate and pentamidine for peruvian cutaneous leishmaniasis Am J Trop Med Hyg 72 2005 133 137
38. J. Blum, P. Desjeux, E. Schwartz, B. Beck, and C. Hatz Treatment of cutaneous leishmaniasis among travelers J Antimicrob Chemother 53 2004 158 166
39. P. Minodier, and P. Parola Cutaneous leishmaniasis treatment Travel Med Infect Dis 5 2007 150 158
40. P. Minodier, G. Noël, P. Blanc, M. Uters, K. Retornaz, and J.M. Garnier Management of cutaneous leishmaniasis in adults and children Med Trop (Mars) 65 2005 487 495
41. M. Nacher, B. Carme, D. Sainte Marie, P. Couppie, E. Clyti, and P. Guibert et al. Influence of clinical presentation on the efficacy of a short course of pentamidine in the treatment of cutaneous leishmaniasis in French Guiana Ann Trop Med Parasitol 95 2001 331 336
42. G. Wortmann, R.S. Miller, C. Oster, J. Jackson, and N. Aronson A randomized, double-blind study of the efficacy of a 10- or 20-day course of sodium stibogluconate for treatment of cutaneous leishmaniasis in United States military personnel Clin Infect Dis 35 2002 261 267
43. B.A. Arana, T.R. Navin, F.E. Arana, J.D. Berman, and F. Rosenkaimer Efficacy of a short course (10 days) of high-dose meglumine antimoniate with or without interferon-gamma in treating cutaneous leishmaniasis in Guatemala Clin Infect Dis 18 1994 381 384
44. M.P. Oliveira-Neto, A. Schubach, M. Mattos, S.C. Goncalves-Costa, and C. Pirmez A low-dose antimony treatment in 159 patients with American cutaneous leishmaniasis: extensive follow-up studies (up to 10 years) Am J Trop Med Hyg 57 1997 651 655
45. M.P. Oliveira-Neto, and S. Mattos Mda An alternative antimonial schedule to be used in cutaneous leishmaniasis when high doses of antimony are undesirable Rev Soc Bras Med Trop 39 2006 323 326
46. M.P. Oliveira-Neto, A. Schubach, M. Mattos, S.C. Gonçalves-Costa, and C. Pirmez Treatment of American cutaneous leishmaniasis: a comparison between low dosage (5 mg/kg/day) and high dosage (20 mg/kg/day) antimony regimens Pathol Biol 45 1997 496 499
47. v) in American cutaneous leishmaniasis: a five years follow-up study of 15 patients Mem Inst Oswaldo Cruz 91 1996 207 209
48. M.P. Oliveira-Neto, A. Schubach, M. Mattos, S.C. da Costa, and C. Pirmez Intralesional therapy on American cutaneous leishmaniasis with pentavalent antimony in Rio de Janeiro, Brazil-an area of Leishmania (V.) braziliensis transmission Int J Dermatol 36 1997 463 468 (Pubitemid 27319639)
49. J. Soto, P. Buffet, M. Grogl, and J. Berman Successful treatment of Colombian cutaneous leishmaniasis with four injections of pentamidine Am J Trop Med Hyg 50 1994 107 111 (Pubitemid 24059993)
50. J. Soto-Mancipe, M. Grogl, and J.D. Berman Evaluation of pentamidine for the treatment of cutaneous leishmaniasis in Colombia Clin Infect Dis 16 1993 417 425 (Pubitemid 23066954)
51. P. Morelli, E. Gianelli, S. Calattini, M. Corbellino, S. Antinori, and L. Meroni Itraconazole can be effective in the treatment of sporotrichoid leishmaniasis J Travel Med 11 2004 328 330 (Pubitemid 39482179)
52. D.S. Jolliffe Cutaneous leishmaniasis from Belize-treatment with ketoconazole Clin Exp Dermatol 11 1986 62 68
53. M. Dan, E. Verner, J. El-on, F. Zuckerman, and D. Michaeli Failure of oral ketoconazole to cure cutaneous ulcers caused by Leishmania braziliensis Cutis 38 1986 198 199 (Pubitemid 16014139)
54. R.E. Saenz, H. Paz, and J.D. Berman Efficacy of ketoconazole against Leishmania braziliensis panamensis cutaneous leishmaniasis Am J Med 89 1990 147 155 (Pubitemid 20254438)
55. A.J. Davis, and L. Kedzierski Recent advances in antileishmanial drug development Curr Opin Invest Drugs 6 2005 163 169 (Pubitemid 43072954)
56. J. El-On, F. Cawich, D.A. Evans, and L. Weinrauch Topical treatment of cutaneous leishmaniasis in Belize: in vitro and in vivo studies with Leishmania mexicana Int J Parasitol 23 1993 121 127 (Pubitemid 23105176)
57. F.J. Andrade-Narvaez, A. Vargas-Gonzalez, S.B. Canto-Lara, and A.G. Damian-Centeno Clinical picture of cutaneous leishmaniasis due to Leishmania(Leishmania) mexicana in the Yucatan peninsula, Mexico Mem Inst Oswaldo Cruz 96 2001 163 167 (Pubitemid 33640922)
58. J. El-on, and G. Messer Leishmania major: antileishmanial activity of methylbenzethonium chloride Am J Trop Hyg 35 1986 1110 1116 (Pubitemid 17210107)
59. B.A. Arana, C.E. Mendoza, N.R. Rizzo, and A. Kroeger Randomized, controlled, double-blind trial of tropical treatment of methylbenzethonium chloride ointment in Guatemala Am J Trop Med Hyg 65 2001 466 470
60. F.A. Neva, C. Ponce, E. Ponce, R. Kreutzer, F. Modabber, and P. Olliaro Non-ulcerative cutaneous leishmaniasis in Honduras fails to respond to topical paromomycin Trans R Soc Trop Med Hyg 91 1997 473 475 (Pubitemid 27421247)
61. R.X. Armijos, M.M. Weigel, M. Calvopina, M. Mancheno, and R. Rodriguez Comparison of the effectiveness of two topical paromomycin treatments versus meglumine antimoniate for New World cutaneous leishmaniasis Acta Trop 91 2004 153 160 (Pubitemid 38952716)
62. J. Soto, P. Fuya, R. Herrera, and J. Berman Topical paromomycin/ methylbenzethonium chloride plus parenteral meglumine antimoniate as treatment for American cutaneous leishmaniasis: controlled study Clin Infect Dis 26 1998 56 58 (Pubitemid 28068155)
63. J. Soto, N. Hernandez, H. Mejia, M. Grogl, and J. Berman Successful treatment of New World cutaneous leishmaniasis with a combination of topical paromomycin/methylbenzethonium chloride and injectable meglumine antimoniate Clin Infect Dis 20 1995 47 51
64. M. Grogl, B.G. Schuster, W.Y. Ellis, and J.D. Berman Successful topical treatment of murine cutaneous leishmaniasis with a combination of paromomycin (aminosidine) and gentamicin J Parasitol 85 1999 354 359 (Pubitemid 29251857)
65. J.M. Soto, J.T. Toledo, P. Gutierrez, M. Arboleda, R.S. Nicholls, and J.R. Padilla Treatment of cutaneous leishmaniasis with a topical antileishmanial drug (WR279396): phase 2 pilot study Am J Trop Med Hyg 66 2002 147 151 (Pubitemid 34755645)
66. M. Solomon, S. Baum, A. Barzilai, A. Scope, H. Trau, and E. Schwartz Liposomal amphotericin B in comparison to sodium stibogluconate for cutaneous infection due to Leishmania braziliensis J Am Acad Dermatol 56 2007 612 616 (Pubitemid 46400168)
67. P. Konecny, and D.J. Stark An Australian case of New World cutaneous leishmaniasis Med J Aust 186 2007 315 317 (Pubitemid 46534239)
68. M. Brown, M. Noursadeghi, J. Boyle, and R.N. Davidson Successful liposomal amphotericin B treatment of Leishmania braziliensis cutaneous leishmaniasis Br J Dermatol 153 2005 203 205 (Pubitemid 41044552)
69. S.L. Croft, R.A. Neal, W. Pendergast, and J.H. Chan The activity of alkylphosphocholines and related derivatives against Leishmania donovani Biochem Pharmacol 36 1987 2633 2636 (Pubitemid 17102920)
70. A. Kuhlencord, T. Maniera, H. Eibl, and C. Unger Hexadecyl phosphocholine; oral treatment of visceral leishmaniasis in mice Antimicrob Agents Chemother 36 1992 1630 1634
71. J. Soto, B.A. Arana, J. Toledo, N. Rizzo, J.C. Vega, and A. Diaz Miltefosine for New World cutaneous leishmaniasis Clin Infect Dis 38 2004 1266 1272 (Pubitemid 38608569)
72. S. Sundar, T.K. Jha, C.P. Thakur, S.K. Bhattacharya, and M. Rai Oral miltefosine for the treatment of Indian visceral leishmaniasis Trans R Soc Trop Med Hyg 100 Suppl 2006 S26 S33
73. B.R. Simeen, A.U. Bari, and M. Nadeem Miltefosine in cutaneous leishmaniasis J Coll Physicians Surg Pak 17 2007 132 135
74. J. Soto, J. Rea, M. Balderrama, J. Toledo, P. Soto, and L. Valda et al. Efficacy of miltefosine for Bolivian cutaneous leishmaniasis Am J Trop Med Hyg 78 2008 210 211
75. J. Soto, and J. Berman Treatment of New World cutaneous leishmaniasis with miltefosine Trans R Soc Trop Med Hyg 100 Suppl 2006 S34 S40 (Pubitemid 44490170)
76. J.T. Soto, J. Toledo, P. Gutierrez, R.S. Nicholls, J. Padilla, and J. Engel et al. Treatment of American cutaneous leishmaniasis with miltefosine, an oral agent Clin Infect Dis 33 2001 E57 E61
77. D.J. Najarian, and J.C. English Imiquimod cream: a new multipurpose topical therapy for dermatology Pharmacy & Therapeutics 28 2003 122 126
78. T.L. Wagner, V.L. Horton, G.L. Carlson, P.E. Myhre, S.J. Gibson, and L.M. Imbertson et al. Induction of cytokines in cynomolgus monkeys by the immune response modifiers, imiquimod, S-27609 and S-28463 Cytokine 9 1997 837 845
79. S. Buates, and G. Matlashewski Treatment of experimental leishmaniasis with the immunoregulators imiquimod and S-28463: efficacy and mode of action J Infect Dis 179 1999 1485 1494
80. C. Miranda-Verastegui, A. Llianos-Cuentas, I. Arevalo, B.J. Ward, and G. Matlashewski Randomized, double-blind clinical trial of topical imiquimod 5% with parenteral meglumine antimoniate in the treatment of cutaneous leishmaniasis in Peru Clin Infect Dis 40 2005 1395 1403
81. I. Arevalo, B. Ward, R. Miller, T.C. Meng, E. Najar, and E. Alvarez et al. Successful treatment of drug-resistant cutaneous leishmaniasis in humans by use of imiquimod, an immunomodulator Clin Infect Dis 33 2001 1847 1851
82. I. Arevalo, G. Tulliano, A. Quispe, G. Spaeth, G. Matlashewski, and A. Llanos-Cuentas et al. Role of imiquimod and parenteral meglumine antimoniate in the initial treatment of cutaneous leishmaniasis Clin Infect Dis 44 2007 1549 1554
83. M.A. Pfaller, and J.J. Marr Antileishmanial effect of allopurinol Antimicrob Agents Chemother 5 1974 469 472
84. S. Martinez, M. Gonzalez, and M.E. Vernaza Treatment of cutaneous leishmaniasis with allopurinol and stibogluconate Clin Infect Dis 24 1997 165 169
85. S. Martinez, and J.J. Marr Allopurinol in the treatment of American cutaneous leishmaniasis N Engl J Med 326 1992 741 744
86. R.H. Guderian, M.E. Chico, M.D. Rogers, K.M. Pattishal, M. Grogi, and J.D. Berman Placebo controlled treatment of Ecuadorian cutaneous leishmaniasis Am J Trop Med Hyg 45 1991 92 97
87. R.E. Saenz, H.M. Paz, C.M. Johnson, J.J. Marr, D.J. Nelson, and K.H. Pattishall et al. Treatment of American cutaneous leishmaniasis with orally administered allopurinol riboside J Infect Dis 160 1989 153 158
88. I. Velez, S. Agudelo, E. Hendrickx, J. Puerta, M. Grogl, and F. Modabber et al. Inefficacy of allopurinol as monotherapy for Colombian cutaneous leishmaniasis: a randomized, controlled trial Ann Intern Med 126 1997 232 236
89. S.M.B. Jeronimo, A. de Queiroz Sousa, and R.D. Pearson Leishmaniasis R.L. Guerrant, D.H. Walker, P.F. Weller, editors. Tropical infectious diseases: principles, pathogens and practice 2nd ed. 2006 Churchill Livingstone Philadelphia 1095
90. C.B. Palatnik-de-Sousa Vaccines for leishmaniasis in the fore coming 25 years Vaccine 26 2008 1709 1724
91. A. Khamesipour, S. Rafati, N. Davoudi, F. Maboudi, and F. Modabber Leishmaniasis vaccine candidates for development: a global overview Indian J Med Res 123 2006 423 438
92. + T cells J Immunol 165 2000 915 924
93. A. Selvapandiyan, R. Duncan, A. Debrabant, N. Lee, G. Sreenivas, and P. Salotra et al. Genetically modified live attenuated parasites as vaccines for leishmaniasis Indian J Med Res 123 2006 455 466
94. S. Gurunathan, D.M. Klinman, and R.A. Seder DNA vaccines: immunology, application and optimization Annu Rev Immunol 18 2000 927 974
95. + T cells are required for primary immunity in C57BL/6 mice following low-dose, intradermal challenge with Leishmania major J Immunol 168 2002 3992 4000
96. + T cell responses and protection against Leishmania major infection J Exp Med 195 2002 1565 1573
97. S.G. Reed Leishmaniasis vaccination: targeting the source of infection J Exp Med 194 2001 F7 F9
98. G. Grimaldi Jr., and R.B. Tesh Leishmaniases of the New World: current concepts and implications for future research Clin Microbiol Rev 6 1993 230 250
99. P. Trouiller, P. Olliaro, E. Torreele, J. Orbinski, R. Laing, and N. Ford Drug development for neglected diseases: a deficient market and a public-health policy failure Lancet 359 2002 2188 2194
100. G. Yamey The world's most neglected diseases BMJ 325 2002 176 177
101. F. Modabber Vaccines against leishmaniasis Ann Trop Med Parasitol 89 Suppl 1995 83 88
102. J.C. Dujardin, L. Campino, C. Cañavate, J.P. Dedet, L. Gradoni, and K. Soteriadou et al. Spread of vector-borne diseases and neglect of leishmaniasis, Europe Emerg Infect Dis 14 2008 1013 1018
103. L.F. Chaves, and M. Pascual Climate cycles and forecasts of cutaneous leishmaniasis, a nonstationary vector-borne disease PLoS Med 3 2006 e295
104. World Health Organization. Leishmaniasis and Leishmania/HIV co-infection. WHO report on global surveillance of epidemic-prone infectious diseases. Available at: http://www.who.int/csr/resources/publications/surveillance/ Leishmaniasis.pdf. Accessed February 7, 2010.
105. C. Bogdan, G. Schönian, A.L. Bañuls, M. Hide, F. Pratlong, and E. Lorenz et al. Visceral leishmaniasis in a German child who had never entered a known endemic area: case report and review of the literature Clin Infect Dis 32 2001 302 306
106. M. Maroli, L. Rossi, R. Baldelli, G. Capelli, E. Ferroglio, and C. Genchi et al. The northward spread of leishmaniasis in Italy: evidence from retrospective and ongoing studies on the canine reservoir and phlebotomine vectors Trop Med Int Health 13 2008 256 264